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 The PROMIS Pain Interference short forms are responsive to change.  
 Their responsiveness are comparable to legacy pain measures.  
 Responsiveness may vary based on the sample and the direction of change.  
 
 
ABSTRACT 
The PROMIS Pain Interference (PROMIS-PI) scales are reliable and publicly accessible; 
however, little is known about how responsive they are to detect change in clinical trials and 
how their responsiveness compares to legacy measures. The study purpose was to evaluate 
responsiveness for the PROMIS-PI scales and to compare their responsiveness with legacy 
pain measures. We used data from three clinical trials totaling 759 participants. The clinical 
trials included patients with chronic low back pain (n= 261), chronic back or osteoarthritis pain (n 
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= 240), and a history of stroke (n= 258). At both baseline and follow-up, participants completed 
PROMIS-PI scales and legacy pain measures (Brief Pain Inventory Interference scale, 
Pain/Enjoyment/General Activity (PEG) scale, SF-36 Bodily Pain scale, and Roland-Morris 
Disability Questionnaire). We measured global ratings of pain change, both prospectively and 
retrospectively, as anchors to identify patients as improved, unchanged, or worsened. 
Responsiveness was assessed with standardized response means, statistical tests comparing 
change groups, and area-under-curve analysis. The PROMIS-PI scales had largely comparable 
responsiveness with the Brief Pain Inventory Interference scale and PEG. The four PROMIS-PI 
short forms had comparable responsiveness. For all pain questionnaires, responsiveness varied 
based on the study population and whether pain improved or worsened.  
Perspective: This paper presents (1) how responsive the PROMIS Pain Interference scales 
were to detect change over time in the context of three clinical trials and (2) how their 
responsiveness compared to legacy pain measures. The findings can help researchers and 
clinicians choose between different patient-reported pain outcome measures.  
Keywords: Pain Interference; Pain Measurement; PROMIS; Responsiveness; Patient-reported 
outcome measures 
 
 
 
1. Introduction 
The National Institutes of Health-funded Patient-Reported Outcomes Measurement 
Information System (PROMIS®) provides researchers and clinicians with outcome measures 
that are reliable, valid, and publicly accessible.1; 3 In contrast to legacy measures, PROMIS® 
emerged from state-of-art psychometric methodologies including item response theory.3 Item 
response theory supports computerized adaptive testing and development of fixed-length short 
forms containing the most informative items.1   
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One key PROMIS® domain is Pain Interference, because pain interference with daily 
activities is a recognized core outcome in pain research and clinical care.1; 8 The PROMIS Pain 
Interference (PROMIS-PI) scales measure the degree to which pain interferes with physical, 
emotional, and social activities, and are available for adults, pediatric self-report, and parent 
proxy-report. The PROMIS-PI scales for adults are the focus of this study. Four fixed-length 
adult PROMIS-PI short forms are available: one with 4 items, two with 6 items, and one with 8 
items.  
Although PROMIS-PI short forms have advantages of brevity, public accessibility, and 
high precision, they are relatively new. Legacy measures–including the Brief Pain Inventory 
(BPI),5 Pain, Enjoyment of Life, General Activity (PEG) scale,17 SF-36 Bodily Pain subscale, and 
Roland-Morris Disability Questionnaire–have been more extensively evaluated in clinical 
populations. It is particularly warranted to evaluate PROMIS-PI’s responsiveness. 
Responsiveness focuses on a measure’s ability to detect changes over time.25 
Researchers sometimes use “responsiveness” interchangeably with “sensitivity to change”. In 
this paper, we use the term responsiveness to prevent potential confusion with the term 
“sensitivity” used in diagnostic research.24 Evidence of responsiveness is vital for cohort studies 
and clinical trials of efficacy/effectiveness. Using measures with good responsiveness minimizes 
the risk of false negative trials and reduces sample size requirements.   
The evidence is limited and mixed about PROMIS-PI responsiveness. Responsiveness 
of PROMIS-PI was supported in a few studies.30,7,2 These studies revealed significant changes 
in PROMIS-PI scores post-treatment 2; 29; 30 or expected relationships between changes in 
PROMIS-PI and anchor measures.7; 21 In other studies, however, the responsiveness of 
PROMIS-PI was not well supported. In one study,12 the PROMIS-PI scale change scores did not 
differ between pain improved and non-improved groups. In another study,14 the PROMIS-PI was 
less responsive than the legacy measures (BPI and PEG).14  
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Previous studies are limited in three ways. First, most studies 2; 7; 12; 21; 29; 30 did not 
compare responsiveness of the PROMIS-PI scales with legacy measures, which precluded 
conclusions regarding relative superiority of measures. Second, five out of six studies 2; 7; 12; 29; 30 
assessed only one version of the PROMIS-PI scales, which precluded head-to-head 
comparisons between PROMIS-PI short forms with different lengths. Third, except for two 
studies,14; 21 PROMIS-PI short forms were not evaluated in the context of clinical trials. More 
evidence on PROMIS-PI’s responsiveness in clinical trials is required before researchers can be 
confident in adopting them as a primary trial outcome.2 
Given the limitations of previous studies, our study purpose was to evaluate 
responsiveness for the fixed-length PROMIS-PI short forms. We evaluated the four PROMIS-PI 
short forms in the context of three clinical trials, and compared responsiveness of the PROMIS-
PI short forms to legacy measures. 
2. Methods 
2.1 Design and Participants 
Data from a total sample of 759 patients were analyzed in this study. Participants were 
recruited from 3 participating clinical trials.  
Sample 1 included 261 participants in the Care Management for the Effective Use of 
Opioids (CAMEO) trial (NCT01236521).18 In the CAMEO trial, patients with moderate to 
severe chronic low back pain were recruited from Veterans Affairs primary care clinics. The 
study tested the effectiveness of pharmacological (opioid management coupled with algorithm-
based co-analgesic treatment) compared to behavioral approaches (education combined with 
pain self-management skills training) for chronic low back pain.  
Sample 2 included 240 participants in the Strategies for Prescribing Analgesics 
Comparative Effectiveness (SPACE) trial (NCT01583985).16 In the SPACE trial, patients with 
chronic back or lower extremity osteoarthritis pain with moderate-severe intensity were recruited 
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from primary care clinics. In this pragmatic trial, effectiveness of two flexible prescribing 
algorithms (opioid-avoidant versus opioid-intensive) were compared.  
Sample 3 included 258 participants in the Stroke Self-Management (SSM) trial 
(NCT01507688). In this clinical trial, stroke survivors were recruited after being discharged from 
a hospital with a primary diagnosis of an acute stroke or transient ischemic attack. In this trial, 
the effectiveness of a stroke self-management intervention was tested against usual care. We 
included this stroke sample for two reasons. First, responsiveness can be context-specific;25 
therefore, evaluating a scale’s responsiveness in various samples with a wide range of pain 
levels is essential. Second, the National Institutes of Health has called for adopting PROMIS® 
measures as common data elements in clinical research, patient registries, and electronic 
medical records to facilitate cross-study comparison and data combination.31 As pain often 
accompanies other medical conditions, PROMIS-PI short forms will likely be increasingly 
adopted in research and clinical settings. Information about their responsiveness beyond the 
context of chronic musculoskeletal pain is needed.   
2.2. Procedures  
The Indiana University Institutional Review Board approved the study. Informed consent 
was obtained from all participants. Self-reported sociodemographic and clinical information was 
collected at baseline. At both baseline and follow-up, participants completed the four PROMIS-
PI short forms, legacy measures, and a global rating of pain (described below). At follow-up, 
retrospective global ratings of pain change since baseline were also collected. The time frames 
for follow-up varied by participating studies. Specifically, follow-up measurement for the CAMEO 
trial was conducted at 6 months after the baseline assessment, while follow-up measurement 
for the SPACE and SSM trials was completed after 3 months. All study questionnaires were 
administered by trained research personnel. 
2. 3. Measurement 
2. 3.1. PROMIS-PI Short Forms.  
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We evaluated four fixed-length PROMIS-PI short forms: 1) the original 6-item pain 
interference Short Form (6b), 2) the 4-item pain interference scale (4a) included in the PROMIS-
29 profile, 3) the 6 item pain interference scale (6a) included in the PROMIS-43 profile, and 4) 
the 8-item pain interference scale (8a) included in the PROMIS-57 profile. In 4a, 6a, and 8a 
short forms, the items are nested: the 6a short form was constructed by adding two items to the 
4a short form and the 8a short form was constructed by adding two items to the 6a short form. 
The original 6-item pain interference short form (6b) shares some but not all of the items as the 
4a, 6a, and 8a short forms. Among the four fixed-length PROMIS-PI short forms, there are 12 
unique items. These unique items were administered at baseline and follow-up.  
We selected fixed-length short forms rather than computer adaptive testing, because in 
many research and clinical contexts, short forms are more feasible to administer. Response 
format was consistent across PROMIS-PI short forms and was based on a 5-point ordinal rating 
scale. The response options were “Not at all,” “A little bit,” “Somewhat,” “Quite a bit,” and “Very 
much.” Raw score totals on each measure were converted to an item response theory-based T-
score using a scoring manual (More information can be found at 
http://www.healthmeasures.net/images/PROMIS/manuals/PROMIS_Pain_Interference_Scoring
_Manual_02232017.pdf). Following this scoring manual, we converted raw scores to T scores 
using the scoring tables. We calculated a scale score for an individual participant only when 
50% or more of items on the short form were answered by that participant; the response scores 
from the answered items were summed, multiplied by the total number of items in the short 
form, and divided by the number of items that were answered. At the item level, the amount of 
missing data was minimal, ranging from 0% to 2.6% of participants across three studies. At the 
scale level, the amount of missing data ranged from 0% to 0.8%.  
The T-score metric allows for directly comparing scores between PROMIS measures of 
different lengths, comparing scores between different samples, and comparing scores to the 
population norm.1 The PROMIS-PI scales were calibrated in the US general population and 
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centered (T-score of 50 equals the mean) on a subsample that represented this reference 
population. This subsample was matched on important demographic variables (e.g., sex, race, 
and education) reported in the 2000 US General Census.1 A higher T-score represents more of 
the construct being measured (i.e., more pain interference).  
2.3.2. Legacy measures  
2. 3.2.1. The Brief Pain Inventory Interference (BPI-I) Scale.   
The BPI is among the most extensively used questionnaires in clinical pain research.5 The 
7-item BPI-I scale measures pain interference on mood, physical activity, work, social activity, 
relations with others, sleep, and enjoyment of life, and is conceptually comparable to the 
PROMIS-PI short forms. Each BPI-I item is scored 0 (“Does not interfere”) to 10 (“Interferes 
completely”), and the BPI-I scale score is the mean score of the 7 interference items. Scores 
range from 0 to 10 with higher scores indicating greater pain interference. The reliability, validity, 
and responsiveness of the BPI are well-established.5 
2. 3.2.2. PEG.  
The PEG is a 3-item pain measure derived from the BPI.17 The three items assess 
average pain intensity (P), interference with enjoyment of life (E), and interference with general 
activity (G). Each item is scored 0 (“no pain” or “does not interfere”) to 10 (“pain as bad as you 
can imagine” or “interferes completely”). The PEG scale score is the mean score of the 3 items. 
Scores range from 0 to 10 with higher scores indicating worse pain. The PEG scale has 
demonstrated reliability, validity, responsiveness to change in different settings.14; 17  
2. 3.2.3. SF Bodily Pain Scale.  
The SF-36 Bodily Pain Scale was administered only in the CAMEO trial. SF-36 Bodily 
Pain is a 2-item subscale of the Medical Outcomes Study SF-36 questionnaire, which has been 
validated in different settings.23 One item assesses pain interference on a 1 (not at all) to 5 
(extremely) scale over the past four weeks. The other item assesses pain severity on a 1 (None) 
to 6 (very severe) scale over the past four weeks. Responses from the 2 items are summed and 
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then transformed to a 0–100 scale to derive a bodily pain subscale score.  
The Roland-Morris Disability Questionnaire. The Roland-Morris Disability 
Questionnaire was administered only in the CAMEO trial. The Roland-Morris Disability 
Questionnaire is a checklist of 24 items assessing pain effects on function.27 The scale score is 
the number of items endorsed with a possible range from 0 to 24 with higher scores indicating 
more pain-related disability. Substantial evidence has accumulated for the validity of the 
Roland-Morris Disability Questionnaire scores to discriminate levels of disability in back pain 
and other chronic pain conditions.13; 23  
2.3.3. Anchor Measures  
2.3.3.1. Retrospective Global Rating of Change 
Our study team used the retrospective global rating of change as one anchor measure. 
The retrospective global rating of change assesses overall clinical response from the 
participant’s perspective.8 At follow-up, participants were asked to rate their pain change 
compared to their pain at baseline assessment. Change in pain is rated on a 7-point scale with 
the following response options: -3 (much worse), -2 (moderately worse), -1 (a little worse), 0 (no 
change), +1 (a little better), +2 (moderately better), or +3 (much better). Based on the rating, 
participants were further categorized into three groups, improved (+1 to +3), unchanged (0), and 
worsened (-1 to -3). The retrospective global rating of change has been widely used to assess 
responsiveness of patient-reported outcome measures.25; 26 Literature supports its validity and 
clinical relevance.8  
2.3.3.2. Prospective Global Rating of Change 
Our study team used the prospective global rating of change as the second anchor 
measure. Specifically, at baseline and follow-up, patients were asked about their pain on 
average in the past 7 days (i.e., cross-sectional global rating of pain). A 5-point ordinal scale 
ranging from 0 = “no pain” to 4 = “very severe pain” was used.32 To calculate the prospective 
global change score, we subtracted the follow-up global ratings of pain from the baseline global 
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ratings of pain. Change scores had a possible range of -4 to +4, where negative numbers 
indicated worsened pain and positive numbers improved pain. Based on the rating, participants 
were further categorized into three groups, improved (+1 to +4), unchanged (0), and worsened 
(-1 to -4).  
We used this prospective anchor to overcome potential recall and reconstruction bias 
related to the retrospective global rating of change.28 A few studies have suggested, compared 
to the retrospective global rating of change, that the prospective global rating of change may be 
less influenced by post-treatment status.10; 28 Therefore, some researchers recommend it as a 
valid anchor for establishing true individual change.10; 28; 32  
2.4. Data Analysis  
We evaluated comparative responsiveness for all four PROMIS-PI short forms and legacy 
measures (i.e., BPI Pain Interference, PEG, SF-36 Bodily Pain, and Roland-Morris Disability 
Questionnaire). Data from each of the three trials were analyzed separately rather than pooled, 
because the three trials involved different clinical populations, study interventions, and follow-up 
timeframes.  
We used both retrospective and prospective global ratings of pain change as the anchors 
(i.e., criteria) to identify patients who have changed since baseline. Specifically, patients were 
categorized into three groups based on global ratings of pain change: improved, unchanged, 
and worsened. Both within-group responsiveness to change and between-group 
responsiveness to change were evaluated as described below.  
2.4.1. Within-group Responsiveness 
For within-group responsiveness, we estimated the amount of change over time within 
each global rating of pain change group (i.e., improved, unchanged, and worsened). 
Standardized response means (SRM) were used as the effect size measure of within-group 
responsiveness to change. The SRM is the ratio of the mean change to the standardized 
deviation (SD) of change, and is calculated using the formula (Mean baseline – Mean follow-up) 
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/ SD of change score. In addition to reporting the point estimates of SRMs, we also calculated 
95% confidence intervals for the SRMs with a bootstrapping procedure. An absolute SRM value 
of 0.2 to 0.5 is considered a small change, 0.5 to 0.8 is moderate, and ≥ 0.8 is large.25 Some 
researchers suggest an absolute SRM value ≥0.3 indicates responsiveness.2  
2.4.2. Between-Group Responsiveness 
For between-group responsiveness, we compared the amount of change between global 
rating of change groups. First, we used omnibus ANOVA tests to compare mean change in 
scale scores across global rating of change groups (i.e., improved, unchanged, and worsened). 
For this analysis, both retrospective and prospective rating of change groups were used as 
anchors. We used post-hoc Tukey-Kramer tests to pair-wise compare the 1) improved and 
unchanged groups, and 2) worsened and unchanged groups. We controlled for family-wise 
Type 1 error at 0.05.  
Second, we used receiver-operating characteristic curve analyses to further quantify a 
measure’s ability to detect improvement. Area under the curve (AUC) is the probability of 
correctly discriminating between patients who have improved and those who have not. The AUC 
values range from 0.5 (the same as chance) to 1.0 (perfect discrimination). We calculated AUC 
for each pain measure using retrospective global rating of change as the anchor. Specifically, 
we evaluated each measure’s ability to detect any improvement ( “a little better”, “moderately 
better”, or “very much better”) as well as moderate improvement (“moderately better” or “very 
much better”). To determine if PROMIS-PI short forms and legacy measures differ in their ability 
to detect improvement, we also statistically compared AUC values between PROMIS-PI and 
legacy measures.6 20 
3. Results 
3.1 Demographic and Clinical Characteristics 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
11 
 
A total of 759 participants completed the baseline and follow-up assessments. 
Demographic characteristics of clinical trial participants have been previously published.4 Briefly, 
baseline data were available on 261 participants in the CAMEO trial, 240 in the SPACE trial, 
and 258 in the SSM trial. CAMEO participants were 92% male, 73% white, with a mean age of 
57.9 years. SPACE participants were 87% male, 86% white, with a mean age of 58.3 years. 
SSM participants were 81% male, 64% white, with a mean age of 61.7 years.4  
Participants in the CAMEO and SPACE trials had greater pain interference than the US 
general population, reflected by their PROMIS-PI mean scores one standard deviation above 
the US population mean.4 Participants in SSM trial had a pain interference level close to the US 
population norm.4 The PROMIS-PI T score has a possible range of 41 to 78 .The PROMIS-PI 
short forms had an observed mean score of 62 (SD=7) at baseline and 60 (SD=8) at follow-up 
in the CAMEO trial, 62 (SD =5) at baseline and 56 (SD=7) at follow-up in the SPACE trial, and 
53 (SD=10.5) at baseline and 53 (SD=10) at follow-up in the SSM trial. Ceiling effects for 
PROMIS-PI measures were negligible; only 0% to 7% of participants responded with the 
maximum possible score (the percentage varied depending on the short form, the trial, and the 
time point). Floor effects, which were also negligible for the pain trials (CAMEO, SPACE; 1% to 
8%), were present for the stroke trial (SSM); 31% to 36% of SSM participants responded with 
the minimum possible score (the percentage varied depending on the short form and time 
point). 
3.2 Within-group Responsiveness 
In Figure 1, within-group effect size estimates (i.e., SRMs) were plotted for the PROMIS-PI 
and legacy measures across 3 trials. This figure provides an overview of comparative within-
group responsiveness across the pain measures. Tables 1 and 2 complement Figure 1 by 
presenting the unstandardized change scores and SRM confidence intervals for the 
retrospective and prospective anchors, respectively.   
Across the PROMIS-PI, BPI-I, and PEG measures, the SRM point estimates were 
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generally similar from a practical standpoint (Figures 1 and 2). In most cases, the confidence 
interval for one measure covered the point estimates of the other measures (Tables 1 and 2), 
which indirectly suggests statistically comparable within-in group responsiveness across these 
three measures. Minor differences in SRMs, however, were observed: For the two samples with 
chronic pain (i.e., CAMEO and SPACE Trials), within the pain improved group, SRMs were 
slightly larger for the PEG than for the PROMIS-PI and BPI-I. For the stroke sample (i.e., SSM 
Trial), however, SRMs for the pain worsened group were slightly larger for the PROMIS-PI 
scales than for the BPI-I and PEG (notably when using retrospective global change as the 
anchor). Based on SRMs, the SF-36-Bodily Pain scale and the Roland-Morris Disability 
Questionnaire appeared less responsive than PROMIS-PI, BPI-I, and PEG; however, data 
comparing these measures were only available for one trial.  
Across the four PROMIS-PI short forms, the SRMs were statistically and practically 
comparable (Figure 2). The differences in SRMs between any two PROMIS-PI short forms were 
within 0.11. Because the SRM estimates for the four PROMIS-PI were quite similar, we reported 
averages of SRMs across the four PROMIS-PI short forms in Figure 1 as well as Tables 1 and 
2. 
For all pain measures, SRMs varied based on the samples and whether pain improved or 
worsened. For the two chronic pain samples with moderate to severe pain, larger effect size 
estimates (i.e., SRMs) were observed in the pain improved groups than in the pain worsened 
groups. Specifically, in the two pain samples, the effect size estimates (i.e., SRMs) for the 
improved group ranged from moderate to large, while SRMs for the worsened group ranged 
from minimal to small. For the pain worsened groups in these two pain samples, a large majority 
of confidence intervals for SRMs included zero. In the stroke sample (i.e., SSM Trial), by 
contrast, larger effect size estimates (i.e., SRM) were observed in the pain worsened groups 
than in the improved groups.  
3.3 Between-group Responsiveness  
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As seen in Tables 1 and 2, all measures successfully detected differences among pain 
improved, unchanged, and worsened groups. Omnibus F-tests were all significant at 0.05 level, 
except for the Roland-Morris Disability Questionnaire when using prospective global pain of 
change as the anchor (p=0.06).  
Figure 3 and Table 3 show the results from the AUC analysis. The PROMIS-PI short 
forms’ probability for accurately detecting any improvement ranged from 0.68 to 0.72 in the two 
pain trials, and ranged from 0.55 to 0.59 in the stroke trial. Similarly, the accuracy of the 
PROMIS-PI short forms in detecting moderate improvement ranged from 0.70 to 0.76 for the 
two pain trials and at a 0.59 level for the non-pain trial.  
The PROMIS-PI short forms performed similarly to legacy measures with a few 
exceptions: In the only pain trial that included the SF-36 Bodily Pain scale (CAMEO), the 
PROMIS-PI short forms had significantly higher accuracy in detecting any improvement and 
moderate improvement than the SF-36 Bodily Pain scale (p values ranged from 0.0003 to 0.01). 
In the other pain trial (SPACE), the PROMIS-PI short forms all had significantly lower accuracy 
in detecting any improvement than the BPI-I and PEG measures (p values ranged from 0.003 to 
0.034). However, in detecting moderate improvement, the PROMIS PI short forms were 
comparable to the BPI-I and PEG.  
4. Discussion 
Using data from three clinical trials, we found PROMIS-PI short forms were responsive 
to change. Moreover, their responsiveness was largely comparable to the BPI-I and PEG 
measures. Consistent with Askew et al.,2 our data indicate that the PROMIS-PI scales are 
responsive to global improvement. Consistent with Deyo et al.,7 PROMIS-PI scores 
discriminated patients whose pain was improved, unchanged, or worsened. Previous studies 
have largely been observational.2; 7; 29; 30 Our study strengthens the evidence by evaluating 
PROMIS-PI responsiveness in the context of three clinical trials.  
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 This study represents a novel effort to compare responsiveness of the PROMIS-PI short 
forms with legacy pain measures. Kean et al. previously reported PROMIS-PI were less 
responsive to global change than BPI-I and PEG.14 By contrast, we found that PROMIS-PI had 
generally comparable responsiveness to BPI and PEG (Figures 1 and 2). The difference 
between our main conclusion and Kean et al.’s may be attributable to two factors. First, Kean et 
al14 used only retrospective global rating of change as the anchor. We used a prospective 
anchor in addition to the retrospective global rating of change anchor to overcome potential 
recall bias related to the retrospective measure. Second, Kean et al. included only one sample 
(persistent musculoskeletal pain), while in our study, responsiveness was evaluated separately 
in trials with three different samples.  
Regarding the possibly poorer responsiveness of the SF-36 Bodily Pain and Roland-
Morris Disability Questionnaire scales, it should be noted these two measures were only 
included in the CAMEO trial. Of note, the SF-36 Bodily Pain scale also appeared less 
responsive in a previous study.15 The SF-36 Bodily Pain scale has a longer recall window (past 
four weeks) compared to PEG, BPI, and PRO IS-PI (past week), and this longer recall window 
may contribute to the lower responsiveness to change.15 However, given the considerable use 
of the SF-36 Bodily Pain and Roland-Morris Disability Questionnaire scales in pain research,11 
further investigation of their comparative responsiveness is warranted. 
Despite the overall comparative responsiveness across PROMIS-PI, BPI-I, and PEG, a 
closer inspection of our findings and Kean et al. suggest the possibility of modest performance 
differences in certain situations. The BPI-I and PEG may be more advantageous when patients 
report high pain and when detecting pain improvement is the priority (e.g., clinical trials of pain 
interventions/treatment). Compared to PROMIS-PI, the BPI-I and PEG had larger effect sizes 
for pain improvement and higher accuracy in detecting any improvement in both our SPACE 
trial and the trial reported by Kean et al. (both trials included patients with moderate to severe 
pain at baseline).14 However, PROMIS-PI may be more advantageous when the study 
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population has a more heterogeneous level of pain and when both pain improvement and 
worsening are of interest. In our stroke trial where baseline pain was mild and no pain-specific 
intervention was involved, PROMIS-PI performed slightly better than BPI-I and PEG in the 
worsened group. The observed differences could be in part attributed to differences in the 
measure development processes. The BPI and PEG were developed in patients with pain using 
classical test theory, while PROMIS-PI were developed in both patients with pain and the 
general population using item response theory. As the PROMIS-PI short forms are derived from 
a longer item bank, it would be possible in the future to derive a short form that is better targeted 
and more responsive to high levels of pain. While these modest responsiveness differences 
across samples with higher and lower levels of pain require further investigation, our collective 
findings integrating both AUC and SRM analyses indicate generally comparable responsiveness 
of the PROMIS-PI, BPI and PEG. Importantly, even though the magnitude of SRMs differed 
somewhat among the scales depending upon the sample, statistical testing comparing AUCs 
confirmed that the scales consistently differentiated both the improved and worsened groups 
from the unchanged group.  
This is among the few studies that used both retrospective and prospective global 
ratings of change as the anchors in assessing responsiveness. Retrospective global rating of 
change has sometimes been criticized because of its potential susceptibility to recall and 
reconstruction bias.9; 28 When using retrospective global rating of change as the anchor, we 
observed some counter-intuitive findings. In one trial (SPACE), patients who retrospectively 
recalled having had worsened pain actually reported improved pain interference. Similarly, the 
qualitative data from the SPACE trial suggested that the participants’ narrative recall of 
treatment effectiveness after interventions did not always match their responder status based on 
change in numerical scores.22 Conversely, Prospective global rating of change which is derived 
by the difference in cross-sectional global ratings of pain at two time points32 is conceptually 
attractive but has not been studied in depth. Thus, integrating findings from these two different 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
16 
 
methods for assessing patient-rated global change may be preferable to relying on one method 
alone. 
Interestingly, responsiveness varied based upon the direction of change and the 
particular sample. Consistent with Askew et al.2 and Deyo et al.,7 our data in two pain trials 
demonstrated a larger magnitude of change for the pain improved group than for the pain 
worsened groups. Specifically, for the pain improved groups, all the pain change scores had 
moderate-to-large effect sizes, and the magnitude of improvement in PROMIS-PI scores were 
above minimally important difference (2-3 points in T score4). For the pain worsened group, 
however, the PROMIS-PIs had minimal-to-small effect sizes, and the magnitude of change in 
PROMIS-PI scores were below minimally important difference.4 The larger SRMs for 
improvement compared to worsening might be due to a couple factors. First, in these two pain 
trials, some patients were exposed to a pain intervention which contributed to a larger effect 
sizes for the improved group. Second, the two pain trials only included patients with moderate to 
severe pain. The restricted room for worsening may have contributed to a small magnitude of 
change in the pain worsening groups. Despite the ceiling effects not being substantial, 
participants in the two pain trials had on average only about 10 points to reach the maximum 
possible scores. The stroke trial participants, compared to the pain trials participants, 
demonstrated a larger magnitude of change in the worsened group, which is likely due to larger 
room for pain to worsen (about 20 points). In the stroke trial, floor effects were present with one-
third participants reporting the minimum possible scores. In addition, the generally mild pain in 
stroke patients created a restrictive room (about 10 points on average) for their pain to improve, 
which may have contributed to the small magnitude of change in the improved group.  
Shorter measures may be as responsive as longer measures. We found that the four 
PROMIS-PI versions ranging from 4 to 8 items had similar responsiveness. The PROMIS-PI 
short forms share some items in common, which may explain in part their comparable 
responsiveness. Likewise, the 3-item PEG was comparable to the 7-item BPI in our trials, 
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replicating findings from three previous studies.14; 15; 20 Short measures may be more desirable 
for large studies with multiple outcome measures, particularly where pain may a secondary 
rather than the primary outcome, or in busy clinical practice settings.  
This study has several strengths. First, we compared the responsiveness of PROMIS-PI 
short forms with widely used legacy pain measures. Second, we used both retrospective and 
prospective global rating of change anchors. Third, we tested responsiveness in the context of 
clinical trials. Fourth, we evaluated responsiveness to change using three clinical samples, each 
of which was large enough for psychometric evaluation. Lastly, we evaluated responsiveness in 
both directions of change (improvement and worsening).   
Our study has several limitations. First, two legacy measures (SF-36 Bodily Pain and 
Roland-Morris Disability Questionnaire) were only used in one trial (CAMEO). We found 
PROMIS appeared superior to these two measures in responsiveness to change; however, 
generalizability of this finding may be limited. Second, our two pain samples had at least 
moderate pain intensity at baseline, leaving a limited room for pain to worsen as discussed 
earlier. Third, we made multiple statistical comparisons between multiple pain measures. 
Readers need to interpret the differences between measures with caution. Fourth, our 
retrospective anchor may reflect a change in pain intensity and/or interference. We selected this 
anchor based on the existing literature; 2; 14; 25; 32 however, it is unknown how participants 
interpreted this anchor item. If participants focused on perceived change on pain intensity rather 
than pain interference, the conceptual difference between pain intensity and interference may 
partially explain some counter-intuitive findings. Nonetheless, pain intensity and interference 
tend to respond in parallel when used as outcome measures in clinical trials.15; 19  
Despite these limitations, this study has several implications for research and clinical 
practice. First, either the PROMIS-PI or legacy measures like BPI or PEG are reasonable 
choices based on responsiveness to change. As the use of the BPI requires a permission from 
the developers and in some circumstances a fee, the freely-available PROMIS-PIs and PEG 
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can be acceptable alternatives. Second, future research is needed to evaluate the comparative 
responsiveness of the PROMIS-PI scales in additional samples. Although this study provided 
support for PROMIS-PI responsiveness, generalizability to other pain populations (e.g., acute, 
recurrent, visceral, neuropathic pain) should be studied. Third, researchers need to further 
evaluate appropriateness of various anchors in assessing responsiveness. The counter-intuitive 
finding regarding retrospective global rating of change we found in one trial was also reported in 
another study.2 Thus, including both prospective and retrospective global rating of change 
anchors may allow researchers to check the robustness of findings.  
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Table 1. Responsiveness by Retrospective Global Pain of Changea 
  CAMEO Trial SPACE Trial SSM Trial 
Pain 
change
 
MeanS
RM 
Scor
e
b
 
chan
ge 
SR
M
c 
(95
% 
CI) 
P-
valu
e
d 
Scor
e
b
 
chan
ge 
SR
M
c 
(95% 
CI) 
P-
valu
e
d
 
Scor
e
b
 
chan
ge 
SR
M
c 
(95
% 
CI) 
P-
valu
e
d
 
PROMI
S 4a 
  
 
 <.00
01 
 
 
 <.00
01 
   <.00
01 
 Bett
er 
.63 4.52 
.60 
(.40
, 
.81) 
.003 6.84 
1.1
0 
(.93, 
1.13) 
.000
2 
1.92 .20 (.0
1, 
.40
) 
.94 
 Sa
me 
.34 1.10 
.23 
(-
.01, 
.46) 
-- 3.27 
.62 
(.37, 
.90) 
-- 1.47 .17 (-
.03, 
.36
) 
-- 
 Wor
se 
-.30 -1.52 
 
−.2
5 
(-
.53, 
.01) 
.066 0.21 
.08 
(-.35, 
.59) 
.089 -6.11 −.7
0 
(-
.99, 
-
.43
) 
<.00
01 
PROMI
S 6a 
  
 
 <.00
01 
 
 
 <.00
01 
   <.00
01 
 Bett
er 
.61 4.66 
.60 
(.39
, 
.83) 
.003 6.92 
1.0
6 
(.92, 
1.2) 
<.00
01 
1.68 .17 (-
.02, 
.36
) 
.99 
 Sa
me 
.32 1.13 
.22 
(−.0
1, 
.44) 
-- 3.05 
.58 
(.31,.
88) 
-- 1.50 .17 (-
.03, 
.36
) 
-- 
 Wor
se 
-.30 -1.45  
−.2
4 
(-
.53, 
.02) 
.082 -0.07    
−.0
1 
(-.46, 
.43) 
.094 -5.81 −.6
5 
(-
.92, 
-
.39
) 
.000
1 
PROMI
S 8a 
  
 
 <.00
01 
 
 
 <.00
01 
   <.00
01 
 Bett
er 
.60 4.17 
.55 
(.35
, 
.79) 
.012 6.69 
1.0
7 
(.92, 
1.25) 
.000
2 
1.72 .18 (-
.01, 
.37
) 
.98 
 Sa
me 
.34 1.15 
.22 
(-
.01, 
.44) 
-- 3.17 
.63 
(.36, 
.95) 
 1.44 .16 (-
.03, 
.36
) 
-- 
 Wor
se 
-.25 -1.71 
 
−.2
8 
(-
.57, 
-
.01) 
.042 0.63 
.16 
(-.27, 
.65) 
.182 -5.54 −.6
3 
(-
.87, 
-
.39
) 
.000
2 
PROMI
S 6b 
  
 
 <.00
01 
 
 
 <.00
01 
   <.00
01 
 Bett
er 
.62 4.45 
.66 
(.46
, 
.000
6 
6.02 1.0
6 
(.92, 
1.22) 
.000
2 
1.36 .14 (-
.06, 
.96 
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.87) .33
) 
 Sa
me 
.30 0.88 
.17 
(-
.06, 
.39) 
-- 2.67 
.53 
(.30, 
.77) 
-- 1.71 .20 (-
.01, 
.39
) 
-- 
 Wor
se 
-.28 -1.10 
 
−.2
0 
(-
.46, 
.06) 
.159 -0.06 
.01 
(-.40, 
.53) 
.103 -5.93 −.6
6 
(-
.91, 
-
.42
) 
<.00
01 
PROMI
S 
average 
  
 
   
 
      
 Bett
er     
.62  
.60 
   1.0
7 
   .17   
 Sa
me     
.33  
.21 
   
.59 
   .18   
 Wor
se  
-.28  −.2
4 
   
.06 
   −.6
6 
  
BPI 
Interfere
nce 
  
 
 <.00
01 
 
 
 <.00
01 
   .024 
 Bett
er     
.71 1.77 
.76 
(.56
, 
.97) 
.000
3 
2.51 
1.2
0 
(1.02, 
1.4) 
<.00
01 
0.43 .17 (-
.02, 
.36
) 
.999 
 Sa
me     
.32 0.51 
.35 
(.09
, 
.61) 
-- 0.64 
.42 
(.18, 
.68) 
-- 0.41 .19 (-
.01, 
.38
) 
-- 
 Wor
se  
-.18 -0.45 
 
−.2
6 
(-
.54, 
.00) 
.019 0.32 
.23 
(-.21, 
.69) 
.78 -0.80 −.2
5 
(-
.56, 
.06
) 
.033 
PEG   
 
 <.00
01 
 
 
 <.00
01 
   .034 
 Bett
er     
.79 1.67 
.77 
(.57
, 
.99) 
.000
5 
2.61 
1.4
3 
(1.25, 
1.6) 
<.00
01 
0.46 .18 (-
.01
, 
.37
) 
.994 
 Sa
me     
.36 0.53 
.31 
(.08
, 
.54) 
-- 0.86 
.60 
(.35, 
.87) 
-- 0.42 .18 (-
.02
, 
.39
) 
-- 
 Wor
se  
-.13 -0.34 
 
−.2
2 
(-
.49, 
.04) 
.028 0.14 
.09 
(-.34, 
.57) 
.203 -0.73 −.2
5 
(-
.57
, 
.06
) 
.048 
SF 
Bodily 
Pain
d
 
  
 
 <.00
01 
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 Bett
er     
 8.13 
.47 
(.29
, 
.66) 
.838  
 
      
 Sa
me     
 6.71 
.54 
(..2
9, 
.79) 
--  
 
      
 Wor
se  
 -3.50  
−.2
0 
(-
.45, 
.04) 
.001  
 
      
Roland-
Morris
d
 
  
 
 <.00
01 
 
 
      
 Bett
er     
 2.90 
.56 
(.40
, 
.73) 
.019  
 
      
 Sa
me     
 1.01 
.27 
(.05
, 
.49) 
--  
 
      
 Wor
se  
 -0.84  
−.2
3 
(-
.49, 
.02) 
.048  
 
      
a
Total N (better, same, worse) with baseline and follow-up data  in CAMEO = 234 (104, 68, 62); in 
SPACE = 222 (134, 66, 22); and in SSM = 238 (102, 96, 40) 
b
Score change = baseline - follow-up (Positive score: improvement, negative score: worsening) 
c 
SRM = baseline – follow-up / SD change score;  
 
d 
Bolded p-values are from omnibus ANOVA tests comparing changes scores among three change groups. 
Other p values were derived from t-test comparing change scores between reference (i.e. “same”) and 
changed (“better” or “worse”) groups and were adjusted for multiple comparison 
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Table 2. Responsiveness by Prospective Global Pain of Changea 
  CAMEO Trial SPACE Trial SSSM Trial 
Pain 
change 
MeanS
RM 
Scor
e
b
 
chan
ge 
SR
M
c
 
 
(95
% 
CI) 
P-
valu
e
d
 
Scor
e
b
 
chan
ge 
SR
M
c
 
 
(95
% 
CI) 
P-
valu
e
d
 
Score
b
ch
ange 
SR
M
c
 
 
(95
% 
CI) 
P-
valu
e
d
 
PROMI
S-PI 4a 
    .000
7 
   <.00
01 
   <.00
01 
 Bett
er      
.87 5.31 .80 (.4
4, 
1.2
) 
.111 8.11 1.2
2 
(0.9
8, 
1.5) 
<.00
01 
5.64 .60 (.4
0, 
.80
) 
<.00
01 
 Sa
me          
.40 2.57 .36 (.1
5, 
.57
) 
-- 3.45 .76 (.59
, 
.95) 
-- 0.47 .08 (-
.12
, 
.28
) 
-- 
 Wor
se     
-.52 -2.39 -.53 (-
.98
, -
.12
) 
.018 -0.82 -.17 (-
.73, 
.35) 
.014 -7.68 -.86 (-
1.2
, -
.59
) 
<.00
01 
PROMI
S-PI 6a 
    .004    <.00
01 
   <.00
01 
 Bett
er      
.83 4.97 .77 (.3
5, 
1.3
) 
.277 8.06 1.1
5 
(.93
, 
1.4) 
<.00
01 
5.47 .57 (.3
8, 
.76
) 
.000
3 
 Sa
me          
.39 2.83 .38 (.1
6, 
.60
) 
-- 3.33 .70 (.52
, 
.89) 
-- 0.61 .10 (-
.10
, 
.29
) 
-- 
 Wor
se    
-.50 -1.95 -.51 (-
.11
, -
.04
) 
.028 -0.41 -.10 (-
.74, 
.40) 
.052 −7.88 -.88 (-
1.2
, -
.62
) 
<.00
01 
PROMI
S-PI 8a 
    .001    <.00
01 
   <.00
01 
 Bett
er     
.87 4.58 .72 (.3
4, 
1.1
) 
.287 7.81 1.1
9 
(.95
, 
1.5) 
<.00
01 
5.68 .61 (.4
3, 
.80
) 
<.00
01 
 Sa
me          
.41 2.54 .36 (.1
4, 
.59
) 
-- 3.49 .77 (.58
, 
.97) 
-- 0.51 .09 (-
.11
, 
.28
) 
-- 
 Wor
se    
-.46 -1.46 -.40 (-
.92
, 
.08
) 
.066 -0.51 -.13 (-
.76, 
.37) 
.024 −7.84 -.86 (-
1.2
, -
.59
) 
<.00
01 
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PROMI
S 6b 
    .006    <.00
01 
   <.00
01 
 Bett
er     
.82 4.75 .69 (.3
5, 
1.1
) 
.053 7.04 1.1
8 
(1.0
0, 
1.4) 
<.00
01 
5.57 .60 (.4
2, 
.78 
.000
3 
 Sa
me          
.36 1.84 .30 (.0
8, 
.52
) 
-- 2.86 .65 (.47
, 
.85) 
-- 0.71 .12 (-
.08
, 
.31
) 
-- 
 Wor
se    
-.40 -0.74 -.20 (-
.76
, 
.29
) 
.26 -0.41 -.10 (-
.74, 
.39) 
.056 −8.51 -.91 (-
1.2
, -
.66
) 
<.00
01 
PROMI
S 
average 
             
 Bett
er     
.85  .75    1.1
9 
   .60   
 Sa
me          
.39  .35    .72    .10   
 Wor
se    
-.47  -.41    -.13    -.88   
BPI 
Interfer
ence 
    <.00
01 
   <.00
01 
   <.00
01 
 Bett
er      
.87 1.66 .65 (.3
5, 
.97
) 
.119 2.70 1.2
1 
(.99
, 
1.4) 
<.00
01 
1.81 .75 (.5
8, 
.93
) 
<.00
01 
 Sa
me          
.50 0.89 .58 (.3
5, 
.83
) 
-- 1.20 .78 (.58
, 
.99) 
-- 0.19 .13 (-
.07
, 
.33
) 
-- 
 Wor
se     
-.50 -1.06 -.57 (-
1.2
, -
.09
) 
.000
7 
-0.13 -.12 (-
.83, 
.38) 
.027 −2.13 -.82 (-
1.1
, -
.57
) 
<.00
01 
PEG     <.00
01 
   <.00
01 
   <.00
01 
 Bett
er      
1.02 2.02 .85 (.6
0, 
1.1
) 
.000
7 
2.85 1.4
5 
(1.2
3, 
1.7) 
<.00
01 
1.93 .77 (.5
9, 
.97
) 
<.00
01 
 Sa
me           
.50 0.67 .45 (.2
4, 
.67
) 
-- 1.30 .94 (.73
, 
1.2) 
-- 0.15 .10 (-
.09
, 
.30
) 
-- 
 Wor
se     
-.60 -1.22 -.87 (-
1.6
.000
3 
-0.13 -.07 (-
.62, 
.007 -2.11 -.87 (-
1.1
<.00
01 
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, -
.34
) 
.45) , -
.64
) 
SF 
Bodily 
Pain
‖
 
    .013         
 Bett
er      
 10.1
8 
.50 (.2
0, 
.80
) 
.296         
 Sa
me          
 5.14 .37 (.1
2, 
.63
) 
--         
 Wor
se     
 -4.44 -.31 (-
1.1
, 
.20
) 
.084         
Roland-
Morris
‖
 
    .055         
 Bett
er      
 2.18 .49 (.1
8, 
.83
) 
.138         
 Sa
me           
 0.62 .16 (-
.05
, 
.38
) 
--         
 Wor
se     
 -0.44 -.10 (-
.59
, 
.40
) 
.59         
a
 Total N (better, same, worse) with baseline and follow-up data in CAMEO = 135 (38, 79, 18); in SPACE 
= 222 (94, 112, 16); and in SSM = 238 (83, 100, 55);  
b
Score change = baseline - follow-up (positive score: improvement, negative score: worsening);  
c 
SRM = baseline – follow-up / SD change score;  
d
bolded P-values are from omnibus ANOVA tests comparing changes scores among 3global ratings of 
change groups. Other P-values are derived from t-test comparing change scores between reference (i.e. 
“same”) and changed (“better” or “worse”) groups and were adjusted for multiple comparison 
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Table 3. Area under the Curve (AUC) for Pain Measures in 3 Trialsa 
Pain 
Scale 
Average accuracy  
across trials 
Accuracy for detecting any 
improvement
b 
Accuracy for detecting 
moderate improvement
b 
 Any 
improvem
ent 
Moder-ate 
improvem
ent 
CAMEO 
 
SPACE 
 
SSM 
 
CAMEO 
 
SPACE 
 
SSM 
 
   AU
C 
(95%
CI) 
AU
C 
(95
% 
CI) 
AU
C 
(95
% 
CI) 
AU
C 
(95
% 
CI) 
AU
C 
(95
% 
CI) 
AU
C 
(95
% 
CI) 
PROMIS 
4a  
.662 .689 .70
8
 
(.640-
.775) 
.69
3
 
(.62
4-
.763
) 
.58
5
 
(.51
3-
.657
) 
.71
9 
(.63
8-
.799
) 
.75
3 
(.68
6-
.819
) 
.59
4 
(.51
8-
.670
) 
PROMIS 
6a 
.655 .679 .71
1 
(.643-
.779) 
.69
6
 
(.62
7-
.766
) 
.55
8
 
(.48
5-
.631
) 
.69
7 
(.60
9-
.784
) 
.75
6 
(.69
0-
.821
) 
.58
5 
(.50
8-
.662
) 
PROMIS 
8a 
.647 .677 .70
4 
(.635-
.773) 
.67
7
 
(.60
7-
.748
) 
.56
0
 
(.48
7-
.633
) 
.69
7 
(.60
7-
.786
) 
.74
9 
(.68
2-
.817
) 
.58
6 
(.50
9-
..66
3) 
PROMIS 
6b 
.659 .688 .72
4 
(.657-
.791) 
.70
0
 
(.63
0-
.769
) 
.55
4
 
(.48
0-
.627
) 
.72
6 
(.64
1-
.811
) 
.74
8 
(.68
0-
.815
) 
.59
0 
(.51
3-
.668
) 
PROMIS 
average 
.656 .683 .71
2 
 .69
2 
 .56
4 
 .71
0 
 .75
2 
 .58
9 
 
BPI 
Interferen
ce 
.677 .683 .72
5 
(.660-
.790) 
.77
0
d 
(.71
0-
.830
) 
.53
5
 
(.46
4-
.606
) 
.69
4 
(.60
4-
.784
) 
.76
4 
(.70
2-
.826
) 
.59
2 
(.51
9-
.665
) 
PEG .682 .691 .72
0 
(.654-
.785) 
.78
7
d 
(.72
8- 
.845
) 
.53
9
 
(.46
7- 
.611
) 
.73
3 
(.64
7- 
.819
) 
.75
3 
(.69
1-
.816
) 
.58
6 
(.511-
.661) 
SF Bodily 
Pain 
  .57
7
c
 
(.503-
.650) 
-- -- -- -- .49
7
c
 
(.39
3-
.601
) 
-- -- -- -- 
  
Roland-
  .67
1 
(.602-
.740) 
-- -- -- -- .65
9 
(.56
3-
-- -- -- -- 
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Morris .755
) 
a
Total N (better, same, worse) with baseline and follow-up data  in CAMEO = 234 (104, 68, 62); in 
SPACE = 222 (134, 66, 22); and in SSM = 238 (102, 96, 40) 
b
Any improvement ≥ “a little better”; moderate improvement ≥ “moderately better”; The AUC’s of the 
PROMIS Pain Interference short forms were mostly comparable to legacy pain measures with a few 
exceptions (below) 
c 
In CAMEO trial, the SF Bodily Pain had significantly lower accuracy in detecting any improvement and 
moderate improvement than the other scales (p values ranged from 0.0003 to 0.01).  
d 
In SPACE trial, the BPI Interference and PEG had significantly higher accuracy in detecting any 
improvement than the PROMIS-PI short forms.  
 
 
